204 related articles for article (PubMed ID: 26872608)
1. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo.
Toth PP; Hamon SC; Jones SR; Martin SS; Joshi PH; Kulkarni KR; Banerjee P; Hanotin C; Roth EM; McKenney JM
Lipids Health Dis; 2016 Feb; 15():28. PubMed ID: 26872608
[TBL] [Abstract][Full Text] [Related]
2. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
Koren MJ; Kereiakes D; Pourfarzib R; Winegar D; Banerjee P; Hamon S; Hanotin C; McKenney JM
J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26586732
[TBL] [Abstract][Full Text] [Related]
3. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
Koren MJ; Roth EM; McKenney JM; Gipe D; Hanotin C; Ferrand AC; Wu R; Dufour R
Postgrad Med; 2015 Mar; 127(2):125-32. PubMed ID: 25609019
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
[TBL] [Abstract][Full Text] [Related]
8. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.
Robinson JG; Rosenson RS; Farnier M; Chaudhari U; Sasiela WJ; Merlet L; Miller K; Kastelein JJ
J Am Coll Cardiol; 2017 Feb; 69(5):471-482. PubMed ID: 28153102
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies).
Teramoto T; Kobayashi M; Uno K; Takagi Y; Matsuoka O; Sugimoto M; Inoue S; Minami F; Baccara-Dinet MT
Am J Cardiol; 2016 Jul; 118(1):56-63. PubMed ID: 27184170
[TBL] [Abstract][Full Text] [Related]
10. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).
Gaudet D; Kereiakes DJ; McKenney JM; Roth EM; Hanotin C; Gipe D; Du Y; Ferrand AC; Ginsberg HN; Stein EA
Am J Cardiol; 2014 Sep; 114(5):711-5. PubMed ID: 25060413
[TBL] [Abstract][Full Text] [Related]
11. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
Kastelein JJ; Ginsberg HN; Langslet G; Hovingh GK; Ceska R; Dufour R; Blom D; Civeira F; Krempf M; Lorenzato C; Zhao J; Pordy R; Baccara-Dinet MT; Gipe DA; Geiger MJ; Farnier M
Eur Heart J; 2015 Nov; 36(43):2996-3003. PubMed ID: 26330422
[TBL] [Abstract][Full Text] [Related]
12. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein profile in patients who survive a stroke.
Oravec S; Krivosikova Z; Krivosik M; Gruber K; Gruber M; Dukát A; Gavorník P
Neuro Endocrinol Lett; 2011; 32(4):496-501. PubMed ID: 21876499
[TBL] [Abstract][Full Text] [Related]
14. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.
Moriarty PM; Parhofer KG; Babirak SP; deGoma E; Duell PB; Hohenstein B; Ramlow W; Simha V; Steinhagen-Thiessen E; Thompson PD; Vogt A; von Stritzky B; Du Y; Manvelian G
J Clin Lipidol; 2016; 10(3):627-34. PubMed ID: 27206951
[TBL] [Abstract][Full Text] [Related]
15. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
16. Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).
Gaudet D; Watts GF; Robinson JG; Minini P; Sasiela WJ; Edelberg J; Louie MJ; Raal FJ
Am J Cardiol; 2017 Jan; 119(1):40-46. PubMed ID: 27793396
[TBL] [Abstract][Full Text] [Related]
17. Alirocumab: A Review in Hypercholesterolemia.
Greig SL; Deeks ED
Am J Cardiovasc Drugs; 2016 Apr; 16(2):141-52. PubMed ID: 26935836
[TBL] [Abstract][Full Text] [Related]
18. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
Leonhardt W; Pfützner A; Müller J; Pietzsch J; Forst T; Karagiannis E; Lübben G; Hanefeld M
Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336
[TBL] [Abstract][Full Text] [Related]
19. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals.
Shrestha S; Volek JS; Udani J; Wood RJ; Greene CM; Aggarwal D; Contois JH; Kavoussi B; Fernandez ML
J Nutr; 2006 Oct; 136(10):2492-7. PubMed ID: 16988115
[TBL] [Abstract][Full Text] [Related]
20. The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes.
Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
Atherosclerosis; 2004 May; 174(1):141-9. PubMed ID: 15135263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
